Erythropoietic Protoporphyria (EPP) Market Set for Steady Growth Through 2036 as Oral Therapies Near the Finish Line | Thelansis

Rising diagnosis rates, a maturing pipeline of oral candidates, and growing payer attention to rare photodermatoses are reshaping the Erythropoietic Protoporphyria (EPP) treatment landscape across the 8 major markets, including China.

Executive Summary
Erythropoietic Protoporphyria (EPP) has spent decades as one of dermatology's most overlooked diagnoses, patients often go years before anyone connects their sun-triggered burning pain to a heme biosynthesis disorder. That's starting to change. With afamelanotide now firmly established as the standard of care and at least three oral candidates working their way through late-stage trials, 2026 is shaping up to be a pivotal year for the EPP and X-linked protoporphyria (XLP) space. Regulatory momentum, expanding genetic testing, and a market projected to grow from roughly USD 850 million in 2025 toward the billions by the mid-2030s are all pointing in the same direction: this ultra-rare disease is finally getting the commercial and clinical attention it deserves.

In this context, Thelansis has published it's flagship reports: Erythropoietic Protoporphyria (EPP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (2026-2036) and Erythropoietic Protoporphyria (EPP) Emerging Therapy, Unmet Needs & TPP Insights Report (2026) - offering a complete, decision-ready view of the disease landscape across the 8 major markets (US, EU4, UK, Japan, and China).

Request a free sample of Thelansis' Erythropoietic Protoporphyria (EPP) Market Outlook and Forecast Report to secure the complete 2026-2036 forecast, exclusive KOL insights, and competitive pipeline data across the 8 Major Markets: https://thelansis.com/reports/erythropoietic-protoporphyria-epp-market-outlook-forecast-2026-to-2036/

Key Emerging Players or Therapies
The pipeline has genuinely diversified beyond the "one approved drug" era, with several distinct mechanisms now competing for the same patient population:
• Dersimelagon (MT-7117) by Mitsubishi Tanabe Pharma - An oral MC1R agonist positioned as a pill-based alternative to afamelanotide's implant. The Phase 3 INSPIRE trial reported positive topline efficacy and safety results in January 2026, a milestone that could support the first oral therapy approval in this space.
• Bitopertin by Disc Medicine - A glycine transporter 1 (GlyT1) inhibitor that lowers PPIX accumulation at its source. The FDA issued a Complete Response Letter in February 2026, but acknowledged that the AURORA and BEACON studies already demonstrate meaningful PPIX reduction; the confirmatory Phase 3 APOLLO study is expected to read out in Q4 2026 and could still support approval.
• PORT-77 by Portal Therapeutics - An orally bioavailable ABCG2 (BCRP) transporter inhibitor in Phase 2a, taking a novel transport-modulation approach to reducing phototoxic reactions.
• Antisense and gene-directed approaches - Academic programs, including cholesterol-conjugated splice-switching oligonucleotides targeting FECH, remain earlier-stage but signal where the science is heading over the next decade.

Key Current Therapies or Standard of Care
• Afamelanotide (Scenesse) - The only FDA- and EMA-approved therapy for EPP, an α-MSH analogue implant that boosts eumelanin production and extends pain-free light tolerance; real-world US cohort data continues to reinforce its quality-of-life benefit.
• Oral beta-carotene - A long-standing supportive option with modest, inconsistent evidence of benefit.
• Photoprotection and behavioral management - Strict sunlight avoidance, protective clothing, and UV-filtering window films remain foundational, even alongside pharmacologic treatment.
• Liver monitoring - Roughly 5% of patients develop protoporphyric hepatopathy, underscoring why longitudinal liver surveillance is now written into consensus management guidelines.

Key Market Drivers/Trends
• Growing physician awareness is cutting the historically long diagnostic delay, expanding the treated and treatable patient pool.
• Multiple late-stage oral candidates could end afamelanotide's decade-long monopoly, intensifying competitive dynamics and pricing pressure.
• Newly published evidence-based consensus guidelines for EPP/XLP diagnosis and management are standardizing care pathways across the 8MM.
• Orphan drug incentives and rare-disease reimbursement frameworks, particularly in the US and EU, continue to de-risk commercial entry.
• China's rare disease registries and growing genetic testing infrastructure are gradually improving diagnosed prevalence estimates in a historically underdiagnosed market.

Key Unmet Need & KOL Expectations
Even with a favorable pipeline, physicians and patient advocates are clear that EPP care is still far from solved. KOLs consistently point to a few priorities:
• An approved oral option, since afamelanotide's implant-and-office-visit model is a real barrier to access for many patients.
• Head-to-head or active-comparator trial designs, rather than repeated placebo-controlled studies against a backdrop of an already-approved therapy.
• Better tools to detect and manage the liver complications that affect a meaningful minority of patients.
• Formal treatment options for adolescents, a population still largely excluded from approved labeling.
• Faster, more reliable diagnostic pathways to shrink the years-long delay between symptom onset and confirmed diagnosis.

Thelansis' Erythropoietic Protoporphyria (EPP) - Emerging Therapy, Unmet Needs & TPP Insights - 2026 examines these evolving trends across the development landscape, helping stakeholders assess future opportunities with greater confidence. Explore the full scope and download a sample: https://thelansis.com/reports/erythropoietic-protoporphyria-epp-emerging-therapy-with-unmet-needs-and-tpp-insights/

TPP Insights
Target product profile expectations emerging from the current data readouts and KOL commentary include:
• Route of administration: Oral dosing is now viewed as a near-mandatory differentiator against the afamelanotide implant.
• Mechanism diversity: Payers and physicians increasingly see value in having options across MC1R agonism, PPIX-synthesis inhibition, and transporter modulation rather than a single mechanism class.
• Biomarker-driven efficacy: PPIX reduction is gaining traction as a regulatory-relevant biomarker, even as agencies continue to weigh it against patient-reported light-tolerance endpoints.
• Adolescent and pediatric extension: Label expansion into younger age groups is expected to be a key value driver for any next-generation therapy.
• Combination potential: Long-term, layered use of photoprotective and pharmacologic strategies is anticipated to remain standard practice even after new approvals.

Our Erythropoietic Protoporphyria (EPP) Emerging Therapy, Unmet Needs & TPP Insights Report (2026) goes deeper on trial designs, target product profiles, and KOL-validated positioning strategies.

Commercial Opportunity
With the EPP/XLP treatment market estimated at roughly USD 850 million in 2025 and projected to expand at a strong double-digit CAGR through the next decade, the commercial runway is real, but so is the execution risk. Companies that can secure oral approval, demonstrate a clean liver-safety profile, and build out rare-disease commercial infrastructure across the 8MM stand to capture a disproportionate share as afamelanotide's exclusivity window narrows. China's evolving rare-disease policy environment adds a longer-term upside for whichever players move early on registration and patient-finding programs.

For a complete, data-backed view of the opportunity - epidemiology-based patient forecasts, competitive benchmarking, pricing and access analysis, and TPP-level strategic guidance - explore both reports:

• Erythropoietic Protoporphyria (EPP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (2026-2036): https://thelansis.com/reports/erythropoietic-protoporphyria-epp-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pr&utm_campaign=epp_mo

• Erythropoietic Protoporphyria (EPP) Emerging Therapy, Unmet Needs & TPP Insights Report (2026): https://thelansis.com/reports/erythropoietic-protoporphyria-epp-emerging-therapy-with-unmet-needs-and-tpp-insights/?utm_source=openpr&utm_medium=pr&utm_campaign=epp_tpp

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

This release was published on openPR.